Olympus Biotech International Ltd and BonAlive Biomaterials Ltd Announce Distribution Agreement

   Olympus Biotech International Ltd and BonAlive Biomaterials Ltd Announce
                            Distribution Agreement

  PR Newswire

  TURKU, Finland and LIMERICK, Ireland, January 21, 2013

TURKU, Finland and LIMERICK, Ireland, January 21, 2013 /PRNewswire/ --

BonAlive Biomaterials Ltd, a manufacturer of implantable medical devices and
an emerging leader in indications involving the treatment of chronically
infected bone, and Olympus Biotech International Ltd, a wholly owned company
of Olympus Corporation focused on minimally-invasive regenerative therapies in
bone and soft tissues, today announced the signing of a multi-year exclusive
distribution agreement. Under the agreement, Olympus Biotech International
will have exclusive distribution rights for the BonAlive ^®  granules product
line in Germany, France and the UK. The product line covers regenerative
products for orthopaedic and trauma  surgeries.

 (Logo: http://photos.prnewswire.com/prnh/20130121/589026-a )

 (Logo: http://photos.prnewswire.com/prnh/20130121/589026-b )

The agreement is an important milestone in the commercialization strategy of
the BonAlive ^® granules product line in the pathway of further expanding the
access to hospitals in the large European markets.

"This newly established partnership enables us to work together with one of
the most prominent leaders in the field of regenerative medicine in providing
a complete portfolio of bone regeneration products to the community of
orthopaedic and trauma surgeons" said Dr. Fredrik Ollila, CEO of BonAlive
Biomaterials Ltd. "The establishment of a complete product offering will
generate value and bring new opportunities in treatment of chronically
infected bone".

"The cooperation and agreement with BonAlive Biomaterials Ltd completes our
bone regeneration portfolio now also in the treatment of fractures and
non-unions in patients with chronic infections. During our thorough global
assessment of different technologies and options we were impressed by the
clinical evidence and clinical data available for BonAlive®. We are very much
convinced to have decided for a partnership with the company having the right
approach to improve patient outcome" said Florian Kemmerich, President of
Olympus Biotech International.

For more information about BonAlive Biomaterials Ltd, please visit
http://www.bonalive.com

For more information about Olympus Biotech, visit
http://www.olympusbiotech.com

About BonAlive Biomaterials Ltd

BonAlive Biomaterials Ltd is an emerging leader in the field of implantable
medical devices for bone regeneration. The focus is to provide world-leading
biomaterial solutions for the treatment of chronically infected bone. BonAlive
^® products are available in Europe, Middle East, Asia-Pacific, Africa, Brazil
and the USA through a professional distributor network. The clinical use of
BonAlive ^® is supported by a twenty year research history including several
randomized prospective trials in the field of spine, benign bone tumor and
trauma surgery. More than fifty peer reviewed articles have been published
about BonAlive ^® .

About Olympus Biotech International Limited

Olympus Biotech was established in December, 2010 as a wholly owned company of
Olympus Corporation. The vision of Olympus Biotech is to improve the patient
Quality of Life by developing and distributing Regenerative Medicine that
stimulates the intrinsic healing capacity in the living body. Olympus Biotech
provides minimally-invasive regenerative therapies for bone and soft tissue
including growth factors, scaffolds and cell harvesting technologies as well
as tools for access, placement and delivery.

For questions or additional information, please contact:

Olympus Biotech International LimitedDirk Dembski Vice President Marketing and
Business Development Olympus Biotech International Mobile +49-172-2492700
dirk.dembski@olympusbiotech.com BonAlive Biomaterials Ltd:Fredrik Ollila, PhD
Chief Executive Officer BonAlive Biomaterials Ltd Mobile+358(0)400-931-209
Fax +358(0)421-917-744-00 fredrik.ollila@bonalive.com
 
Press spacebar to pause and continue. Press esc to stop.